KindlyMD's Persistent Low Stock Price Threatens Nasdaq Listing

KindlyMD, a publicly traded Bitcoin treasury company operating under the ticker NAKA, is confronting a critical challenge that could result in its removal from Nasdaq trading. The core issue stems from its stock’s inability to recover above the $1 mark—a threshold that exchanges use to evaluate company viability. With its stock trading at just $0.38, the company now faces a regulatory countdown that will determine its future on the exchange.

Racing Against the Delisting Clock: Critical Timelines

The situation carries specific regulatory requirements that create an urgent timeline. KindlyMD’s low stock price has persisted for 30 consecutive trading days, triggering Nasdaq’s delisting protocol. To avoid removal from the exchange, the company must engineer a recovery: its stock needs to climb above $1 and remain there for a minimum of 10 consecutive trading days. The deadline for this turnaround is June 8, 2026—leaving approximately five months for execution.

The company’s struggles trace back to late October 2025, when its stock first dipped below the $1 threshold. The situation deteriorated significantly from May 2025, when KindlyMD reached its all-time high. Since that peak, the stock has crashed nearly 99%, reflecting a dramatic loss of investor confidence and market value.

Substantial Bitcoin Holdings Amid Trading Struggles

Despite its current trading difficulties, KindlyMD maintains a substantial digital asset position that distinguishes it within corporate treasuries. The company holds 5,398 Bitcoins, positioning it as the 19th largest corporate Bitcoin holder globally. This significant crypto holdings stack represents meaningful value, even as the company’s equity struggles find its footing in the public markets.

Understanding the Company’s Recent Transformation

KindlyMD’s current predicament cannot be separated from its recent corporate restructuring. The company underwent a reverse merger with Nakomoto in August 2025, a transaction designed to establish its presence on Nasdaq. However, the strategic move has not yet translated into stock price stability, leaving investors and stakeholders navigating substantial uncertainty about the company’s trading future.

The convergence of low stock price pressures and the Nasdaq listing requirement creates a high-stakes scenario. KindlyMD must demonstrate operational recovery and regain investor confidence within the window provided by regulators. How the company addresses this challenge will determine whether it maintains its public listing status through mid-2026.